JFG
RYTM icon

Jefferies Financial Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Jefferies Financial Group’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,100
Closed -$906K – 1738
2025
Q1 		$906K Buy
+17,100
New +$949K 0.01% 845
2024
Q4 		– Sell
-18,000
Closed -$943K – 1812
2024
Q3 		$943K Buy
+18,000
New +$862K 0.01% 804
2024
Q2 		– Sell
-68,566
Closed -$2.97M – 1821
2024
Q1 		$2.97M Sell
68,566
-13,495
-16% -$591K 0.03% 455
2023
Q4 		$3.77M Sell
82,061
-41,599
-34% -$1.31M 0.02% 481
2023
Q3 		$2.83M Sell
123,660
-510
-0.4% -$11.4K 0.03% 510
2023
Q2 		$2.05M Buy
124,170
+113,397
+1,053% +$2.05M 0.02% 651
2023
Q1 		$192K Buy
+10,773
New +$271K ﹤0.01% 1360

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jefferies Financial Group's RYTM Position: Q2 2025 in Review

Jefferies Financial Group sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2025, closing a stake of 17,100 shares — an estimated $906K sold.

Jefferies Financial Group first reported a position in RYTM in Q1 2023 and held it in 7 quarters. The position peaked at $3.77M in Q4 2023. 227 funds tracked by Wall St. Rank hold RYTM as of Q2 2025.

  • Jefferies Financial Group reported no remaining Rhythm Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Jefferies Financial Group sold 17,100 Rhythm Pharmaceuticals shares in Q2 2025, an estimated $906K.
  • Jefferies Financial Group first reported a position in Rhythm Pharmaceuticals in Q1 2023 and held it in 7 quarters.
  • Jefferies Financial Group's Rhythm Pharmaceuticals position peaked at $3.77M in Q4 2023.
  • 227 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2025.

Based on Jefferies Financial Group's 13F filing for Q2 2025, filed 12 Aug 2025.